论文部分内容阅读
目的探讨米氮平与潘立酮联合治疗对高血压合并抑郁焦虑症患者尿蛋白的影响。方法选取2014年1月到2016年1月于我院就诊的高血压合并抑郁焦虑症患者180例,将患者按照入院编号,随机分为三组,A、B、C三组各60例患者,A组患者采用米氮平30mg,1/次天治疗;B组患者采用潘立酮150mg,1/次天治疗;C组患者采用联合治疗法,疗程均为2周,治疗后观察三组患者尿蛋白肾功改善情况及降压效果。结果 C组患者在接受治疗后,平均尿微量白蛋白含量(19.86±5.1mmol.L~(-1))vs.(38.5±5.0 mmol.L~(-1))、(37.6±5.0 mmol.L~(-1)),β2-微球蛋白含量(0.50±1.5mg/L)vs.(0.85±1.0mg/L)、(0.73±1.5mg/L)和平均血压值(115.6±10.5mm Hg)vs.(130.2±12.2 mm Hg)、(135.5±10.5mm Hg)均低于A组患者和B组患者,差异均有统计学意义(P<0.05)。结论米氮平结合潘立酮治疗高血压合并抑郁焦虑症能有效改善患者的尿蛋白含量及血压状态,获得理想治疗效果。
Objective To investigate the effect of combination therapy of mirtazapine and pirolidone on urinary protein in patients with hypertension and depression-anxiety. Methods One hundred and eighty patients with hypertension and depression and anxiety who were treated in our hospital from January 2014 to January 2016 were selected and randomly divided into three groups according to their admission numbers. Sixty patients in each of A, B and C groups were enrolled in this study. A group of patients with mirtazapine 30mg, 1 / day treatment; B group of patients with perlone 150mg, 1 / day treatment; C group were treated with combination therapy for 2 weeks after treatment were observed in three groups of patients Urinary protein kidney function to improve the situation and antihypertensive effect. Results The average urine microalbuminuria (19.86 ± 5.1mmol.L -1), (38.5 ± 5.0 mmol.L -1) and (37.6 ± 5.0 mmol. (0.50 ± 1.5 mg / L) vs. (0.85 ± 1.0 mg / L), (0.73 ± 1.5 mg / L) and mean blood pressure (115.6 ± 10.5 mm (130.2 ± 12.2 mm Hg) and (135.5 ± 10.5 mm Hg) were lower than those in group A and group B, respectively. The differences were statistically significant (P <0.05). Conclusion The combination of mirtazapine and paliperidone in the treatment of hypertension and depression-anxiety disorder can effectively improve the urinary protein level and blood pressure status of patients and achieve the desired therapeutic effect.